Related by context. All words. (Click for frequent words.) 78 metastatic castration resistant 76 castration resistant prostate cancer 74 prostate cancer HRPC 73 castrate resistant prostate cancer 71 metastatic castrate resistant 71 relapsed ovarian cancer 71 prostate cancer mCRPC 71 metastatic prostate cancer 70 mRCC 70 recurrent glioblastoma multiforme 70 leukemia AML 70 prostate cancer AIPC 70 unresectable stage 69 androgen deprivation 69 metastatic hormone refractory 69 IV NSCLC 69 pancreatic adenocarcinoma 69 stage IIIB 69 prostate carcinoma 69 unresectable tumors 69 fallopian tube carcinoma 69 recurrent NSCLC 69 clinically localized prostate 69 metastatic renal cell carcinoma 69 HRPC 69 prostate cancer CaP 68 HER2 positive metastatic breast 68 mapatumumab 68 metastatic gastric 68 bevacizumab Avastin ® 68 goserelin 68 androgen independent 67 metastatic malignant melanoma 67 LHRH receptor positive 67 metastatic RCC 67 mCRC patients 67 erlotinib Tarceva ® 67 hormone refractory 67 superficial bladder cancer 67 sorafenib Nexavar 67 recurrent prostate cancer 67 invasive candidiasis 67 docetaxel Taxotere ® 67 leukemia CLL 67 Myelodysplastic Syndrome MDS 67 external beam radiotherapy 67 cetuximab Erbitux ® 67 refractory prostate cancer 67 cell lymphoma CTCL 67 recurrent glioblastoma 67 sipuleucel T 67 metastatic androgen independent 67 colorectal carcinoma 67 Ophena 66 GnRH agonists 66 biliary tract cancer 66 CYT# potent vascular disrupting 66 adjuvant radiotherapy 66 MAGE A3 ASCI 66 hormone refractory prostate cancer 66 palliative radiotherapy 66 benign prostatic hypertrophy 66 malignant pleural mesothelioma 66 prostate cancer PCa 66 gastrointestinal stromal tumors GIST 66 metastatic GIST 66 invasive aspergillosis 66 FOLFOX4 66 estramustine 66 metastatic malignant 66 Proxinium TM 66 Adjuvant chemotherapy 66 benign prostatic hypertrophy BPH 66 IL# PE#QQR 65 colorectal cancer liver metastases 65 prostate adenocarcinoma 65 malignant ascites 65 hormone deprivation 65 Cloretazine 65 IV metastatic melanoma 65 IRX 2 65 hepatocellular carcinoma HCC 65 CR# vcMMAE 65 colorectal liver metastases 65 Nexavar sorafenib 65 secondary hyperparathyroidism 65 luteinizing hormone releasing 65 galiximab 65 NSCLC 65 ovarian carcinoma 65 metastatic colorectal 65 standard chemotherapy regimen 65 ELACYT 65 axitinib 65 alkylating agent 65 cancer mCRC 65 PKC# 65 medically inoperable 65 castrate resistant 65 cytoreductive surgery 65 situ CIS 65 hormone refractory metastatic prostate 65 Hepatocellular Carcinoma HCC 65 cisplatin chemotherapy 65 cilengitide 65 cetuximab Erbitux R 65 recurrent GBM 65 pegylated liposomal doxorubicin 65 hyperplasia BPH 65 Hormone Refractory Prostate Cancer 65 docetaxel chemotherapy 65 Aflibercept 65 chronic HCV 65 Pemetrexed 65 urothelial cancer 65 Surgical resection 65 stage IIIB IV 65 imatinib therapy 65 metastatic CRPC 65 Degarelix 65 5 Fluorouracil 65 locoregional recurrence 65 PCa 65 pan HDAC inhibitor 65 Hodgkin lymphoma NHL 65 refractory ovarian cancer 65 HGS ETR1 65 lymphoma CTCL 65 localized prostate cancer 64 AVODART 64 Neoadjuvant 64 oblimersen 64 transplantation HCT 64 oral prodrug 64 HGS ETR2 64 relapsed AML 64 trastuzumab Herceptin ® 64 flutamide 64 resistant hormone refractory 64 Genasense ® 64 renal tumors 64 antiangiogenic therapy 64 metastatic neuroendocrine tumors 64 ritonavir boosted 64 leukemia ALL 64 PROSTVAC VF 64 Doxil ® 64 endometrial hyperplasia 64 HNSCC 64 neoplasia 64 seminoma 64 pancreatic carcinoma 64 riociguat 64 adjuvant radiation 64 mycophenolate mofetil 64 Mitoxantrone 64 lintuzumab SGN 64 gefitinib Iressa 64 dasatinib Sprycel ® 64 peritoneal carcinomatosis 64 stage IIIb 64 radiotherapy RT 64 CMV disease 64 secondary hypogonadism 64 mutated KRAS gene 64 mycosis fungoides 64 relapsed MM 64 minimally symptomatic 64 imatinib Gleevec 64 Cutaneous T 64 Elotuzumab 64 epithelial ovarian 64 gemcitabine Gemzar 64 phase IIb clinical 64 esophageal candidiasis 64 CINTREDEKIN BESUDOTOX 64 operable breast cancer 64 pertuzumab 64 NMIBC 64 treat benign prostatic 64 relapsing remitting multiple sclerosis 64 adjuvant therapy 64 androgen suppression therapy 64 relapsed ALL 64 recurrent ovarian cancer 64 Pralatrexate 64 hepatocellular cancer 64 thalidomide Thalomid 64 radical prostatectomy RP 64 cediranib 64 assessing T DM1 64 PROVENGE sipuleucel T 64 oral deforolimus 64 medullary thyroid cancer 64 HBeAg negative 64 trastuzumab Herceptin R 64 chemoradiotherapy 64 locoregional 64 clodronate 64 EBRT 64 ALND 64 Malignant Melanoma 64 evaluating tivozanib 64 vinca alkaloid 64 haematological cancers 64 Aviptadil 64 mCRPC 64 IV melanoma 64 relapsed multiple myeloma 64 symptomatic benign prostatic 64 DAPT 64 bevacizumab Avastin 64 K ras mutations 64 completely resected 64 minimally symptomatic metastatic castrate 64 metastatic HRPC 63 anti angiogenic agents 63 refractory acute myeloid 63 CBLC# 63 metastatic pancreatic 63 recurrent malignant glioma 63 PREZISTA r 63 gastrointestinal stromal tumor GIST 63 gastric adenocarcinoma 63 Enzyme Replacement Therapy 63 ribavirin RBV 63 undergoing radical prostatectomy 63 taxane resistant 63 Adjuvant therapy 63 lupus nephritis 63 NATRECOR ® 63 recurrent ovarian 63 Benign Prostatic Hyperplasia BPH 63 symptomatic BPH 63 neoadjuvant chemotherapy 63 chemoresistant 63 perioperatively 63 vinorelbine 63 unresectable 63 keloid scarring 63 EFAPROXYN 63 Irinotecan 63 myeloproliferative disorders 63 FOLFOX6 63 primary immunodeficiency PI 63 Trastuzumab 63 asymptomatic metastatic 63 CD3 monoclonal antibody 63 haematologic malignancies 63 serum calcium levels 63 KRAS mutation 63 Glioblastoma Multiforme 63 Motexafin Gadolinium 63 relapsed SCLC 63 Vidaza azacitidine 63 neoadjuvant therapy 63 GnRH agonist 63 IMA# 63 pain palliation 63 Azacitidine 63 adecatumumab 63 AEG# 63 adalimumab Humira 63 idarubicin 63 relapsed leukemia 63 cetuximab Erbitux 63 pomalidomide 63 oral ridaforolimus 63 refractory gout 63 relapsing MS 63 Taxotere chemotherapy 63 taxane chemotherapy 63 oral leukoplakia 63 bone metastasis 63 advanced NSCLC 63 antibody MAb 63 abiraterone 63 elacytarabine 63 Cloretazine ® 63 FSAD 63 MyVax R 63 decitabine 63 PEGylated interferon beta 1a 63 MGd 63 recurrent glioma 63 CTAP# Capsules 63 5 FU leucovorin 63 forodesine 63 refractory CLL 63 Critical Limb Ischemia CLI 63 Romidepsin 63 liver metastases 63 cytoreduction 63 cystectomy 63 Ophena TM 63 Atypical Hemolytic Uremic Syndrome 63 lymphoid malignancies 63 Myelodysplastic Syndrome 63 breast carcinoma 63 adenomatous 63 cytotoxic therapy 63 metastatic colorectal cancer 63 HuMax EGFr 63 trastuzumab DM1 63 canakinumab 63 carboplatin paclitaxel 63 corticosteroid dexamethasone 63 lintuzumab 63 nonmetastatic prostate cancer 63 HER2 positive breast cancer 63 Erlotinib 63 heavily pretreated 63 cabazitaxel 63 relapsing multiple sclerosis 63 resected pancreatic cancer 63 panobinostat 62 candidemia 62 alvespimycin 62 chemopreventive agent 62 5-fluorouracil/leucovorin 62 myelodysplastic syndromes MDS 62 antiretroviral naïve 62 stage IIIb IV 62 Carcinoma 62 essential thrombocythemia ET 62 olaparib 62 PEGylated Fab fragment 62 pheochromocytoma 62 recurrent metastatic 62 allogeneic hematopoietic stem cell 62 pancreatic neuroendocrine tumors 62 peritoneal cancer 62 humanised monoclonal antibody 62 plus prednisone 62 interferon gamma 1b 62 gastrointestinal stromal tumor 62 LHRH agonist 62 interferon ribavirin 62 basal cell carcinoma BCC 62 docetaxel Taxotere R 62 FOLFIRI 62 chemotherapy cisplatin 62 chemoembolization 62 refractory multiple myeloma 62 phase IIb trial 62 HSP# inhibitor 62 Actinic Keratosis 62 Natalizumab 62 everolimus eluting stents 62 refractory chronic lymphocytic 62 Virulizin ® 62 ancrod 62 Femara letrozole 62 PRTX 62 malignant lymphomas 62 vidofludimus 62 epithelial tumors 62 receptor tyrosine kinase inhibitor 62 Ozarelix 62 nonsmall cell lung cancer 62 dasatinib Sprycel 62 metastatic disease 62 inhibitor RG# 62 FASLODEX 62 hyperphenylalaninemia HPA due 62 mertansine 62 nab paclitaxel 62 investigational monoclonal antibody 62 refractory colorectal cancer 62 GW# [003] 62 Dasatinib 62 Chronic Myelogenous Leukemia CML 62 OMP #R# 62 Chronic Myeloid Leukemia 62 mutated KRAS 62 non splenectomized 62 FOLOTYN ® 62 chronic lymphocytic leukemia CLL 62 erlotinib Tarceva 62 bladder carcinoma 62 intravesical therapy 62 Cytoxan 62 nucleoside analog 62 Temsirolimus 62 Melphalan 62 pamidronate 62 antitumor effect 62 Helicobacter pylori eradication 62 hormonal therapy 62 Sapacitabine 62 advanced epithelial ovarian 62 platelet inhibitor 62 Targretin 62 anthracycline taxane 62 PAOD 62 Personalized Immunotherapy 62 interferon therapy 62 unstable angina UA 62 glufosfamide 62 EGFR mutation 62 FUSILEV enhances 62 curative resection 62 PNP inhibitor 62 demonstrated antitumor activity 62 epirubicin cyclophosphamide 62 Myelofibrosis 62 ZOLINZA 62 trabectedin 62 gastrointestinal stromal tumors 62 ADPKD 62 Mitomycin C 62 HIV HCV coinfected 62 endocrine therapies 62 metastatic ovarian cancer 62 metastatic bladder 62 fulvestrant 62 interferon alfa 2b 62 NATRECOR R 62 INCB# [001] 62 5 fluorouracil leucovorin 62 cisplatin gemcitabine 62 hepatic metastases 62 glucocorticoid induced osteoporosis 62 T1a 62 familial amyloidotic polyneuropathy FAP 62 lapatinib Tykerb 62 previously untreated follicular 62 LHRH agonists 62 Cystectomy 62 grade cervical intraepithelial 62 huC# DM4 62 vandetanib 62 dacarbazine 62 cisplatin resistant 62 KRAS mutant tumors 62 thromboembolic events 62 prostate pancreatic 62 Azedra 62 Gleevec imatinib 62 Candida infection 62 Campath alemtuzumab 62 Gefitinib 62 resistant ovarian cancer 62 adriamycin 62 INCB# [003] 62 Navelbine ® 62 phase IIb study 62 PSMA ADC 62 castration resistant 62 pediatric malignancies 62 Renal Cell Carcinoma 62 thromboembolic complications 62 terlipressin 62 antiandrogens 62 GISTs 62 differentiated thyroid 62 HeFH 62 metastatic renal cell 62 urothelial bladder cancer 62 Meets Primary Endpoint 62 neoadjuvant 62 bicalutamide 62 alefacept 62 alfa 2a 62 Afatinib 62 aflibercept VEGF Trap 62 Herceptin trastuzumab 62 tumors GIST 62 velafermin 62 Androxal ® 62 HQK 62 teriflunomide 62 alfuzosin 62 B7 H3 62 advanced hepatocellular carcinoma 62 Metastatic Melanoma 62 TTF Therapy 62 postoperative chemotherapy 62 ALA PDT 62 ribavirin therapy 62 multiple myeloma MM 62 Chronic Myeloid Leukemia CML 62 histone deacetylase inhibitor 62 nonmetastatic 62 abiraterone acetate 62 Velcade bortezomib 62 intravenous bisphosphonates 62 Elocalcitol 62 cutaneous melanoma 62 adjuvant chemotherapy 62 Androxal TM 61 paclitaxel Taxol R 61 YONDELIS 61 stable angina 61 tumor recurrence 61 Gliadel Wafer 61 alpha 2a 61 R lenalidomide 61 Peginterferon alfa 2b 61 allogeneic stem cell 61 hormone LHRH antagonist 61 metastatic lung cancer 61 lomitapide 61 Aplidin 61 dexpramipexole 61 histologically confirmed 61 cinacalcet 61 Acute Radiation Syndrome ARS 61 sarcomatoid 61 carcinoid tumors 61 Relapsed Refractory 61 evaluating picoplatin 61 Gleevec resistant 61 anti EGFR antibody 61 Advanced Melanoma 61 anti androgen 61 urothelial carcinoma 61 biochemical recurrence 61 immunomodulatory therapy 61 Cell Lymphoma 61 radioiodine therapy 61 herpetic keratitis 61 idiopathic pulmonary fibrosis IPF 61 Tavocept 61 CA4P 61 pancreatic NET 61 Dupuytren Disease 61 atherothrombotic events 61 talactoferrin 61 erythropoietic 61 anti leukemic 61 immunocompetent 61 Abiraterone acetate 61 DU #b 61 BRAF mutation 61 epithelial ovarian cancer 61 Metastatic Colorectal Cancer 61 refractory NSCLC 61 standard chemotherapy regimens 61 dacarbazine chemotherapy 61 fosbretabulin 61 Diabetic Macular Edema 61 pegylated liposomal doxorubicin PLD 61 metaglidasen 61 Plicera 61 gemcitabine carboplatin 61 basiliximab 61 efalizumab 61 Hypogonadism 61 primary hypercholesterolemia 61 postmenopausal osteoporotic women 61 transthyretin amyloidosis 61 Enzastaurin 61 Advanced Renal Cell 61 APOPTONE 61 5-FU/LV 61 refractory AML 61 anthracycline containing 61 β blockers 61 CaP 61 paclitaxel carboplatin 61 KRAS mutations occur 61 cangrelor 61 Bezielle 61 EGFR inhibitors 61 PRT# 61 testosterone deficiency 61 Pharmacokinetics PK 61 mixed hyperlipidemia 61 non metastatic osteosarcoma 61 non squamous NSCLC 61 alkylating agents 61 EVIZON 61 atypical Hemolytic Uremic Syndrome 61 ® lenalidomide 61 Nilotinib 61 Insegia 61 EGFR TKI 61 Squamous 61 myelofibrosis polycythemia vera 61 selective modulator 61 null responder 61 papillary renal cell carcinoma 61 eosinophilic asthma 61 renal carcinoma 61 azacytidine 61 indolent follicular non 61 Androgen deprivation therapy 61 Diffuse Large B 61 Immunotherapeutic 61 efaproxiral 61 GP IIb IIIa inhibitors 61 lenalidomide dexamethasone 61 androgen deprivation therapy 61 liver metastasis 61 AA Amyloidosis 61 Alocrest 61 paclitaxel poliglumex 61 CMV infections 61 HGS ETR1 mapatumumab 61 trastuzumab Herceptin 61 EGFR tyrosine kinase inhibitors 61 bevacizumab Avastin R 61 distant metastases 61 esophageal carcinoma 61 myelodysplastic myeloproliferative diseases 61 Refractory Hodgkin Lymphoma 61 BENICAR HCT 61 cell carcinomas 61 amrubicin 61 paclitaxel eluting stents 61 relapsing remitting MS RRMS 61 Cell Lymphoma CTCL 61 Capesaris 61 Toxicities 61 T1DM 61 Androgen Deprivation Therapy 61 LibiGel ® 61 Amrubicin 61 azacitidine 61 metastatic cancer 61 fluvastatin 61 CYC# 61 IV malignant melanoma 61 abacavir Ziagen 61 cytoreductive nephrectomy 61 NAVISTAR R 61 Radical prostatectomy 61 temsirolimus 61 localized renal 61 MYCN amplification 61 Oral Fingolimod 61 neuroendocrine tumors 61 irinotecan doxorubicin oxaliplatin paclitaxel 61 acute myelogenous leukemia AML 61 posaconazole 61 undergone radical prostatectomy 61 transplantation HSCT 61 folinic acid 61 ACTEMRA TM 61 Stage IIIb 61 caspofungin 61 pancreatic insufficiency 61 INSPIRE Trial Phase III 61 imatinib Gleevec ® 61 gastrointestinal cancers 61 R Saizen R 61 TACI Ig 61 lenalidomide Revlimid R 61 angiogenesis inhibition 61 XELOX 61 intestinal metaplasia 61 LHRH analogues 61 Sezary syndrome 61 acetonide FA 61 fallopian tube cancers 61 palifermin 61 T#I [002] 61 Vicinium TM 61 HuLuc# 61 underwent resection 61 TKI therapy 61 Monotherapy 61 p# biomarkers 61 thymoma 61 cholangiocarcinoma 61 Bevacizumab 61 dexrazoxane 61 non squamous 61 FOLFOX chemotherapy 61 chemoradiation therapy 61 invasive ductal 61 MYDICAR ® 61 pCR 61 tamoxifen therapy 61 CEQ# 61 davunetide intranasal AL 61 preoperative chemotherapy 61 Hodgkin lymphoma HL 61 sorafenib tablets 61 TRAIL R1 61 pharmacokinetic PK study 61 Interferon Beta 61 weekly subcutaneous injections 61 Flu Cy 61 Fludara ® 61 PXD# 61 Vascugel 61 Multiple Myeloma MM 61 neoplastic lesions 61 Phase 2b Clinical Trial 61 hA# 61 Metastatic Prostate Cancer 61 EGFR mutations 61 SHPT 61 metastatic kidney 61 JAK inhibitors 61 depsipeptide 61 FIRMAGON 61 Annamycin 61 Prostate AdenoCarcinoma Treatment 61 VFEND 61 H. pylori eradication 61 advanced adenomas 61 pelvic malignancies 61 prospectively defined 61 trans retinoic acid 61 allogeneic HSCT 61 rhITF 61 EOquin TM 61 octreotide implant 61 ISTODAX 61 TELINTRA 61 kidney urologic 61 Tezampanel 61 baminercept 61 Acute Coronary Syndromes ACS 61 lumiliximab 61 nonalcoholic steatohepatitis NASH 61 Imprime PGG 61 liposomal amphotericin B 61 mitoxantrone plus 61 small molecule tyrosine 61 alpha1 antitrypsin deficiency 61 severe renal impairment 61 beta 1a 61 p# biomarker 61 flavopiridol 61 rapid virologic response 61 radiation sensitizer 61 Folfox 60 acute GvHD 60 interferon alfa 2a 60 TNF alpha antagonist 60 tesmilifene 60 endometrial cancers 60 microsphere therapy 60 sorafenib 60 overactive bladder OAB 60 Bortezomib 60 hepatic fibrosis 60 therapeutic regimens 60 paricalcitol 60 nonischemic 60 mucinous 60 resectable 60 lymphocytosis 60 lung fibrosis 60 debulking surgery 60 GIST tumors 60 TLK# 60 Eculizumab 60 biochemical relapse 60 TACE 60 systemically administered 60 undergoing androgen deprivation 60 Complicated Skin 60 myeloid metaplasia 60 mTOR inhibitors 60 ALK inhibitor 60 sunitinib Sutent 60 non alcoholic steatohepatitis 60 elotuzumab 60 androgen deficiency 60 soluble tumor necrosis 60 busulfan 60 Epidermal Growth Factor Receptor 60 ZYBRESTAT 60 docetaxel prednisone 60 renal cell carcinoma 60 EGFR HER2 60 gemcitabine chemotherapy 60 Capecitabine 60 diabetic gastroparesis 60 Fludara 60 idiopathic myelofibrosis 60 KRAS mutations 60 chronic eosinophilic leukemia 60 hepatocellular carcinoma liver 60 Phase IIIb clinical 60 abacavir lamivudine 60 nodal metastasis 60 radiolabeled TM# 60 osteopenic 60 Fludarabine 60 hormone LHRH agonist 60 catheter occlusion 60 complement inhibitor eculizumab 60 neratinib 60 acute humoral rejection 60 orchiectomy 60 HCV infected 60 mucosal healing 60 prostate cancer 60 docetaxel Taxotere 60 Patients Treated With 60 TO AVOID PREGNANCY WHILE 60 SPRYCEL ® 60 mitomycin C 60 SAR# [004] 60 Paraplatin ® 60 hypercholesterolemic patients 60 myeloproliferative diseases 60 Onrigin 60 papillary carcinoma 60 relapsed refractory multiple myeloma 60 zoledronic acid 60 anaplastic 60 immunoconjugate 60 HER2 negative 60 cyclophosphamide methotrexate 60 GRASPA ® 60 T2DM 60 targeting CD# 60 liver transplant recipients 60 pelvic lymphadenectomy 60 subependymal giant cell 60 choroidal neovascularization 60 DCVax ® Brain 60 KRAS status 60 pouchitis 60 Acute Myeloid Leukemia 60 CCX# 60 irinotecan containing 60 budesonide foam 60 advanced metastatic renal 60 relapsed CLL 60 Phase #/#a trial 60 superficial basal cell carcinoma 60 PDX pralatrexate 60 #I TM# 60 Vidofludimus 60 Renal Cell Carcinoma RCC 60 situ LCIS 60 recurrent VTE 60 HBeAg positive 60 Idiopathic Pulmonary Fibrosis 60 FEMALES SHOULD BE ADVISED 60 HoFH 60 mCRC 60 lipid lowering therapies 60 lobular carcinoma 60 JAK2 inhibitor 60 micafungin 60 radiation therapy SBRT 60 invasive lobular carcinoma 60 hematologic disorders 60 Rituxan rituximab 60 contralateral breast 60 pulmonary metastasis 60 Panzem R NCD 60 locoregional disease 60 TORISEL 60 pT2 60 Fluorouracil 60 VNP#M 60 pharmacokinetic interactions 60 paclitaxel Taxol 60 octreotide 60 Kit CD# positive 60 gastric atrophy 60 MALT lymphoma 60 androgen ablation 60 Vidaza ® 60 systemic anaplastic large 60 pegylated interferon alfa 2a 60 renal cell carcinomas 60 Torisel 60 OHR/AVR# 60 Vandetanib 60 cytotoxic chemotherapy 60 hepatocellular carcinoma 60 Dacogen decitabine 60 Golimumab 60 APTIVUS r 60 IV bisphosphonates 60 low dose cytarabine 60 virus HCV protease inhibitor 60 factor G CSF 60 renal transplantation 60 zoledronic acid Zometa 60 Castration Resistant Prostate Cancer 60 entinostat 60 Cetrorelix 60 neoadjuvant setting 60 liposomal formulation 60 antiplatelet therapy 60 ganetespib 60 CIMZIA ™ 60 telaprevir dosed 60 omega interferon 60 potent CYP#A# inhibitors 60 colon carcinoma 60 Trofex 60 STRIDE PD 60 tyrosine kinase inhibitors TKIs 60 systemic lupus erythematosus SLE 60 cisplatin vinorelbine 60 Sorafenib 60 PROLARIS 60 Squalamine 60 plus dexamethasone 60 ATTR CM 60 malignant neoplasms 60 CCR9 antagonist 60 decompensated cirrhosis 60 Relapsing Remitting Multiple Sclerosis 60 pegfilgrastim 60 hematological cancers 60 potentially hepatotoxic 60 ischemic cardiomyopathy 60 abnormal uterine bleeding 60 Hurthle cell 60 pralatrexate 60 calcineurin inhibitor 60 sodium thiosulfate STS 60 Motesanib 60 acute promyelocytic leukemia 60 unresectable locally advanced 60 Navelbine 60 ON #.Na 60 OvaRex ® MAb 60 INTEGRILIN R 60 rituximab refractory 60 denileukin diftitox 60 LHRH antagonist 60 chlorambucil 60 Anthracycline 60 pleural mesothelioma 60 adjuvant tamoxifen 60 carcinoid 60 XYOTAX TM 60 gastroesophageal junction 60 metastatic colon cancer 60 tiuxetan 60 Solazed TM 60 ara C 60 Apaziquone 60 zalutumumab 60 ZACTIMA 60 Tarceva TM 60 SUPPRELIN R LA 60 IFN alfa 60 SSc 60 irinotecan chemotherapy 60 commercialize deforolimus 60 thrombocytopenic 60 Quinamed 60 Phase Ib II 60 systemic RNAi therapeutic 60 PROSTVAC TM 60 metastatic CRC 60 premalignant 60 AVASTIN 60 vemurafenib 60 exocrine pancreatic insufficiency EPI 60 humanized anti 60 Barrett esophagus BE 60 thymalfasin 60 unresectable liver cancer 60 tumor lysis syndrome 60 sunitinib 60 antitumour activity 60 bendamustine 60 corticosteroid therapy 60 hepatoma 60 enzastaurin 60 Acute Myelogenous Leukemia AML 60 chronic periodontitis 60 chronic myeloid 60 vismodegib 60 Rheumatoid Arthritis RA 60 TNF antagonist 60 CIMZIA TM certolizumab pegol 60 Mantle Cell Lymphoma 60 Copegus ribavirin 60 Tyrima 60 variceal hemorrhage 60 phase IIa clinical 60 pulmonary metastases 60 SCCHN 60 skeletal metastases 60 sitaxsentan 60 PEG SN# 60 tocilizumab 60 chemoradiation 60 severe aortic stenosis 60 dose escalation clinical 60 IFN beta 60 chronic ITP patients 60 leiomyomas 60 trastuzumab DM1 T DM1 60 trastuzumab 60 Ceflatonin 60 dyslipidaemia 60 microwave hyperthermia 60 non hodgkin lymphoma 60 BRIM2 60 Traficet EN